|
Jun 28
|
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
|
|
Jun 27
|
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
|
|
Jun 13
|
Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
|
|
May 8
|
Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Agenus First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
May 8
|
Agenus Inc (AGEN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...
|
|
May 7
|
Agenus (AGEN) Q1 2024 Earnings Call Transcript
|
|
May 7
|
Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 7
|
Agenus Inc (AGEN) Q1 2024 Earnings: Misses Revenue and EPS Estimates Amid Strategic Developments
|
|
May 7
|
Agenus Reports First Quarter 2024 Results
|
|
May 7
|
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
|
|
May 1
|
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
|
Apr 28
|
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
|
|
Apr 24
|
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
|
|
Apr 23
|
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
|
|
Apr 22
|
Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?
|
|
Apr 12
|
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
|
|
Apr 8
|
Down 75%. Is Agenus Stock a Buy on the Dip?
|
|
Apr 5
|
Agenus Announces Reverse Stock Split of Common Stock
|
|
Apr 3
|
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
|